549. Clinical Characteristics and Outcomes of Patients with COVID-19 treated with Convalescent Plasma in Miami, Florida

• Published in: Open forum infectious diseases Vol. 7; no. Supplement_1; pp. S340 - S341
• Main Authors: Anjan, Shweta, Skiada, Dimitra, Cuartas, Miriam Andrea Duque, Salguero, Douglas, Serota, David P, Gonzales-Zamora, Jose, Ayoade, Folusakin, Beauchamps, Laura, Quiroz, Tanya R, Bertran-Lopez, Jovanna, Raccamarich, Patricia, Montgomerie, Emily K, Barreto, Irma, Abbo, Lilian M, Doblecki-Lewis, Susanne, Wu, Yanyun, Alcaide, Maria L
• Format: Journal Article
• Language: English
• Published: US Oxford University Press 31-12-2020
• Subjects: Poster Abstracts
• ISSN: 2328-8957; 2328-8957
• DOI: 10.1093/ofid/ofaa439.743

Abstract
Background
The Coronavirus disease of 2019 (COVID-19) global health crisis caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has resulted in unprecedented mortality, impacted society, and strained healthcare systems, yet sufficient data regarding treatment options are lacking. Convalescent plasma, used since 1895 for infectious disease outbreaks, offers promise as a treatment option for COVID-19.
Methods
This is a retrospective study of patients diagnosed by a nasopharyngeal swab SARS-CoV-2 reverse transcriptase–polymerase chain reaction (RT-PCR), who received convalescent plasma between April to June 2020 at two large hospitals in Miami, Florida, as part of the US FDA Expanded Access Program for COVID-19 convalescent plasma (CCP).
Results
A total of 23 patients received CCP, 13 (57%) had severe COVID-19 disease, while 8 (35%) had critical or critical with multiorgan dysfunction. Median time of follow up was 26 (range, 7–79) days. Overall, 11 (48%) survived to discharge, 6 (26%) died, while 6 (26%) are currently hospitalized. All deaths reported were due to septic shock from secondary infections. 15 (65%) showed improvement in oxygen requirements 7 days post CCP transfusion. Measured inflammatory markers, c-reactive protein, lactate dehydrogenase, ferritin and d-dimer improved 7 days post transfusion in 13 (57%) patients. No adverse events due to the transfusion were reported. 10 (43.4%) patients had a negative SARS-CoV-2 RT-PCR at a median of 14.5 (range, 4–31) days after receiving convalescent plasma.
Conclusion
Administration of convalescent plasma was found to be safe, with favorable outcomes in this small cohort of relatively high acuity patients. Larger studies including control arms are needed to establish the efficacy of convalescent plasma on clinical and virologic outcomes for patients with COVID-19.
Table
Disclosures
All Authors: No reported disclosures